Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:tofacitinib
go back to main search page
Accession:CHEBI:71200 term browser browse the term
Definition:A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.
Synonyms:exact_synonym: 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile
 related_synonym: CP 690550;   Formula=C16H20N6O;   InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1;   InChIKey=UJLAWZDWDVHWOW-YPMHNXCESA-N;   SMILES=C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N;   Tasocitinib;   tofacitinibum
 alt_id: MESH:C479163
 xref: CAS:477600-75-2;   Drug_Central:4713;   KEGG:D09970;   LINCS:LSM-1227
 xref_mesh: MESH:C479163
 xref: PDBeChem:MI1;   PMID:21952978;   PMID:21971513;   PMID:22006202;   PMID:22147632;   PMID:22233204;   PMID:22357358;   PMID:22460142;   PMID:22474037;   PMID:22525048;   PMID:22576568;   PMID:22591402;   PMID:22607178;   PMID:22607938;   PMID:22682022;   PMID:22802024;   PMID:22873530;   PMID:22873531;   PMID:22894574;   PMID:22899318;   PMID:22916341;   PMID:22924949;   PMID:22960764;   PMID:23055694;   PMID:23150969;   PMID:23150970;   PMID:23150971;   Patent:WO2007012953;   Patent:WO2007107318;   Patent:WO2010123919;   Reaxys:11647225;   Wikipedia:Tofacitinib


show annotations for term's descendants           Sort by:
tofacitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA] CTD PMID:21383241 NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases metabolic processing ISO AKR1C1 protein results in increased metabolism of tofacitinib metabolite CTD PMID:27117606 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein] CTD PMID:21383241 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ampd2 adenosine monophosphate deaminase 2 multiple interactions
decreases expression 		ISO [tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine CTD PMID:25496463 NCBI chr 2:195,707,609...195,720,454
Ensembl chr 2:195,707,610...195,720,271 		JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression ISO tofacitinib results in decreased expression of BST2 mRNA CTD PMID:25487280 NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
multiple interactions 		ISO tofacitinib results in decreased expression of CCL2 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein] 		CTD PMID:22121136 PMID:23968543 PMID:25398374 PMID:36416909 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] CTD PMID:36416909 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein] CTD PMID:22121136 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Ccnd1 cyclin D1 increases expression ISO tofacitinib results in increased expression of CCND1 mRNA CTD PMID:26300391 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ctsk cathepsin K decreases expression ISO tofacitinib results in decreased expression of CTSK protein CTD PMID:21937456 NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:183,058,569...183,069,550 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases expression
decreases secretion
multiple interactions 		ISO
EXP 		tofacitinib results in decreased expression of CXCL10 mRNA
tofacitinib results in decreased secretion of CXCL10 protein
tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein] 		CTD PMID:22121136 PMID:22899318 PMID:22941906 PMID:24213371 PMID:25398374 More... NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 decreases expression
multiple interactions 		ISO tofacitinib results in decreased expression of CXCL11 mRNA
tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA] 		CTD PMID:22941906 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 decreases expression ISO tofacitinib results in decreased expression of CXCL13 mRNA CTD PMID:25398374 NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933 		JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 multiple interactions
decreases expression 		ISO tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]
tofacitinib results in decreased expression of CXCL9 mRNA 		CTD PMID:22941906 PMID:24213371 NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases metabolic processing ISO CYP1A2 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 increases metabolic processing ISO CYP2C19 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing ISO CYP2D6 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
increases oxidation 		ISO CYP3A4 protein results in increased metabolism of tofacitinib
CYP3A4 protein results in increased oxidation of tofacitinib metabolite 		CTD PMID:27117606 PMID:31414593 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Gli1 GLI family zinc finger 1 increases expression ISO tofacitinib results in increased expression of GLI1 mRNA CTD PMID:25487280 NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:63,156,926...63,169,251 		JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 decreases expression ISO tofacitinib results in decreased expression of IFI27 mRNA CTD PMID:25487280 NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294 		JBrowse link
G Ifi35 interferon-induced protein 35 decreases expression ISO tofacitinib results in decreased expression of IFI35 mRNA CTD PMID:25487280 NCBI chr10:86,381,023...86,389,279
Ensembl chr10:86,381,010...86,389,952 		JBrowse link
G Ifi44 interferon-induced protein 44 decreases expression ISO tofacitinib results in decreased expression of IFI44 mRNA CTD PMID:25487280 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844 		JBrowse link
G Ifit3 interferon-induced protein with tetratricopeptide repeats 3 decreases expression ISO tofacitinib results in decreased expression of IFIT3 mRNA CTD PMID:25487280 NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 decreases expression ISO tofacitinib results in decreased expression of IFITM1 mRNA CTD PMID:25487280 NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169 		JBrowse link
G Ifna1 interferon, alpha 1 multiple interactions ISO tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925 		JBrowse link
G Ifng interferon gamma multiple interactions ISO tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IFNG protein]
tofacitinib affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of CXCL8 protein]; tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of IL1B protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein] 		CTD PMID:21383241 PMID:22941906 PMID:24213371 PMID:33130239 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein] CTD PMID:21383241 PMID:24285838 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] CTD PMID:36416909 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903 		JBrowse link
G Il15 interleukin 15 multiple interactions ISO tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein] CTD PMID:21155605 NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820 		JBrowse link
G Il17a interleukin 17A multiple interactions ISO tofacitinib inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of and results in increased secretion of IL17A protein] CTD PMID:26738536 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression 		ISO
EXP 		tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]
tofacitinib results in decreased expression of IL1B mRNA
tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of IL1B protein]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA] 		CTD PMID:21383241 PMID:21937456 PMID:22899318 PMID:22941906 PMID:33130239 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il2 interleukin 2 multiple interactions ISO tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:21155605 PMID:21383241 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566 		JBrowse link
G Il21 interleukin 21 multiple interactions ISO tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein] 		CTD PMID:21383241 NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996 		JBrowse link
G Il23a interleukin 23 subunit alpha multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein] CTD PMID:21383241 PMID:21937456 NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923 		JBrowse link
G Il23r interleukin 23 receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA] CTD PMID:21383241 NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein] CTD PMID:21383241 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions 		ISO
EXP 		tofacitinib results in decreased expression of IL6 mRNA
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA]
tofacitinib results in decreased expression of and results in decreased secretion of IL6 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA] 		CTD PMID:21383241 PMID:21548952 PMID:21844139 PMID:21937456 PMID:22121136 More... NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il6r interleukin 6 receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein] CTD PMID:21548952 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536 		JBrowse link
G Irf7 interferon regulatory factor 7 decreases expression ISO tofacitinib results in decreased expression of IRF7 mRNA CTD PMID:22941906 PMID:25487280 NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832 		JBrowse link
G Irf9 interferon regulatory factor 9 decreases expression ISO tofacitinib results in decreased expression of IRF9 mRNA CTD PMID:25487280 NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236 		JBrowse link
G Isg15 ISG15 ubiquitin-like modifier decreases expression ISO tofacitinib results in decreased expression of ISG15 mRNA CTD PMID:25487280 NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435 		JBrowse link
G Jak1 Janus kinase 1 decreases activity
multiple interactions 		ISO tofacitinib results in decreased activity of JAK1 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein] 		CTD PMID:21548952 PMID:23968543 PMID:24883332 NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jak2 Janus kinase 2 affects response to substance
decreases activity
multiple interactions 		ISO JAK2 gene mutant form affects the susceptibility to tofacitinib
tofacitinib results in decreased activity of JAK2 protein
tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein] 		CTD PMID:21548952 PMID:21844139 PMID:23968543 PMID:26300391 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Jak3 Janus kinase 3 decreases activity
multiple interactions 		ISO tofacitinib results in decreased activity of JAK3 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein] 		CTD PMID:21548952 PMID:23689514 PMID:23968543 PMID:24883332 PMID:26300391 More... NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein] CTD PMID:22941906 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Klhl31 kelch-like family member 31 increases expression ISO tofacitinib results in increased expression of KLHL31 mRNA CTD PMID:25487280 NCBI chr 8:78,515,514...78,538,873
Ensembl chr 8:78,515,514...78,538,873 		JBrowse link
G Krt16 keratin 16 decreases expression ISO tofacitinib results in decreased expression of KRT16 mRNA CTD PMID:27059729 NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799 		JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor multiple interactions EXP tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA] CTD PMID:27708194 NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein] CTD PMID:21548952 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein] CTD PMID:21548952 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein] CTD PMID:21548952 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein] CTD PMID:21548952 NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mmp1 matrix metallopeptidase 1 decreases expression ISO tofacitinib results in decreased expression of MMP1 mRNA CTD PMID:25398374 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097 		JBrowse link
G Mmp3 matrix metallopeptidase 3 decreases expression ISO tofacitinib results in decreased expression of MMP3 mRNA CTD PMID:25398374 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA] CTD PMID:24285838 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I increases expression ISO tofacitinib results in increased expression of COX1 protein CTD PMID:25487280 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867 		JBrowse link
G Mx1 MX dynamin like GTPase 1 decreases expression ISO tofacitinib results in decreased expression of MX1 mRNA CTD PMID:25487280 NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507 		JBrowse link
G Mx2 MX dynamin like GTPase 2 decreases expression ISO tofacitinib results in decreased expression of MX2 mRNA CTD PMID:25487280 NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342 		JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein] CTD PMID:22941906 NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028 		JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 multiple interactions ISO tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein] CTD PMID:22941906 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213 		JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A decreases expression ISO tofacitinib results in decreased expression of OAS1 mRNA CTD PMID:25487280 NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517 		JBrowse link
G Oas2 2'-5' oligoadenylate synthetase 2 decreases expression ISO tofacitinib results in decreased expression of OAS2 mRNA CTD PMID:25487280 NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371 		JBrowse link
G Osm oncostatin M multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]
tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of S100A7 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein] 		CTD PMID:21548952 PMID:21937456 PMID:23968543 PMID:25252914 NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313 		JBrowse link
G Prdm16 PR/SET domain 16 increases expression ISO tofacitinib results in increased expression of PRDM16 protein CTD PMID:25487280 NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601 		JBrowse link
G Prl prolactin multiple interactions EXP tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein] CTD PMID:27708194 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062 		JBrowse link
G Relb RELB proto-oncogene, NF-kB subunit multiple interactions ISO tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein] CTD PMID:22941906 NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507 		JBrowse link
G Rorc RAR-related orphan receptor C multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA] CTD PMID:21383241 NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907 		JBrowse link
G Rsad2 radical S-adenosyl methionine domain containing 2 decreases expression ISO tofacitinib results in decreased expression of RSAD2 mRNA CTD PMID:25487280 NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699 		JBrowse link
G Sdha succinate dehydrogenase complex flavoprotein subunit A increases expression ISO tofacitinib results in increased expression of SDHA protein CTD PMID:25487280 NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:28,940,164...28,961,535 		JBrowse link
G Sele selectin E decreases expression EXP tofacitinib results in decreased expression of SELE mRNA CTD PMID:22899318 NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741 		JBrowse link
G Selp selectin P decreases expression EXP tofacitinib results in decreased expression of SELP mRNA CTD PMID:22899318 NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845 		JBrowse link
G Sfrp5 secreted frizzled-related protein 5 increases expression ISO tofacitinib results in increased expression of SFRP5 mRNA CTD PMID:25487280 NCBI chr 1:241,006,762...241,011,224
Ensembl chr 1:241,006,762...241,011,224 		JBrowse link
G Shh sonic hedgehog signaling molecule increases expression ISO tofacitinib results in increased expression of SHH mRNA CTD PMID:25487280 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 decreases expression ISO tofacitinib results in decreased expression of SOCS3 mRNA CTD PMID:25487280 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 decreases expression
decreases phosphorylation
multiple interactions 		ISO tofacitinib results in decreased expression of STAT1 mRNA; tofacitinib results in decreased expression of STAT1 protein modified form
tofacitinib results in decreased phosphorylation of STAT1 protein
tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]
tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein] 		CTD PMID:21383241 PMID:21548952 PMID:22121136 PMID:22941906 PMID:23968543 More... NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
G Stat2 signal transducer and activator of transcription 2 multiple interactions ISO tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases activity
decreases phosphorylation
decreases expression
multiple interactions 		ISO tofacitinib results in decreased activity of STAT3 protein
tofacitinib results in decreased phosphorylation of STAT3 protein
tofacitinib results in decreased expression of STAT3 protein modified form
tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein] 		CTD PMID:21383241 PMID:21548952 PMID:21844139 PMID:21937456 PMID:22121136 More... NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
multiple interactions 		ISO
EXP 		tofacitinib results in decreased phosphorylation of STAT5A protein
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein] 		CTD PMID:21155605 PMID:22705984 PMID:26244872 PMID:27708194 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases phosphorylation
multiple interactions 		ISO
EXP 		tofacitinib results in decreased phosphorylation of STAT5B protein; tofacitinib results in decreased phosphorylation of STAT5B protein mutant form
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] 		CTD PMID:21155605 PMID:22705984 PMID:26244872 PMID:27708194 PMID:29200404 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668 		JBrowse link
G Stat6 signal transducer and activator of transcription 6 multiple interactions ISO tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein] CTD PMID:21383241 NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA] CTD PMID:21383241 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IFIT1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]; tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein]; tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]
tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA] 		CTD PMID:21383241 PMID:21937456 PMID:22121136 PMID:22941906 PMID:25487280 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf10 TNF superfamily member 10 decreases expression ISO tofacitinib results in decreased expression of TNFSF10 mRNA CTD PMID:25487280 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions
decreases expression 		ISO
EXP 		tofacitinib results in decreased expression of and results in decreased secretion of TNFSF11 protein
tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]
tofacitinib results in decreased expression of TNFSF11 mRNA
tofacitinib results in decreased expression of TNFSF11 protein 		CTD PMID:21937456 PMID:22899318 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445 		JBrowse link
G Ucp1 uncoupling protein 1 increases expression
multiple interactions 		ISO tofacitinib results in increased expression of UCP1 mRNA; tofacitinib results in increased expression of UCP1 protein
cyclopamine inhibits the reaction [tofacitinib results in increased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA] 		CTD PMID:25487280 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852 		JBrowse link
G Usp18 ubiquitin specific peptidase 18 decreases expression ISO tofacitinib results in decreased expression of USP18 mRNA CTD PMID:25487280 NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO tofacitinib results in increased expression of VEGFA mRNA CTD PMID:26300391 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20845
    chemical entity 20843
      group 20786
        pseudohalo group 4665
          cyano group 4665
            nitrile 4665
              tofacitinib 87
                tofacitinib citrate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20845
    subatomic particle 20843
      composite particle 20843
        hadron 20843
          baryon 20843
            nucleon 20843
              atomic nucleus 20843
                atom 20843
                  main group element atom 20766
                    main group molecular entity 20766
                      s-block molecular entity 20561
                        hydrogen molecular entity 20545
                          hydrides 19679
                            inorganic hydride 18572
                              pnictogen hydride 18558
                                nitrogen hydride 18469
                                  azane 18229
                                    ammonia 18228
                                      organic amino compound 18228
                                        tertiary amino compound 10243
                                          tofacitinib 87
                                            tofacitinib citrate 0
paths to the root